Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Endpoints
Sat, 09/18/21 - 08:29 pm
ESMO
Merck
Keytruda
Roche
Avastin
cervical cancer
World Lung 2021 – front-line competition lines up behind Keytruda
EP Vantage
Tue, 09/14/21 - 10:43 am
World Lung
Merck
Keytruda
CStone Pharmaceuticals
Shanghai Junshi Biosciences
lung cancer
Merck Investors Have Reason to Cheer This Label Expansion
Motley Fool
Thu, 09/9/21 - 10:54 am
Merck
Keytruda
Japan
triple negative breast cancer
Merck's Keytruda survives FDA scrutiny in bladder cancer, but ends up with a smaller label
Fierce Pharma
Wed, 09/1/21 - 01:26 pm
Merck
Keytruda
FDA
bladder cancer
The sellside’s most controversial products
EP Vantage
Tue, 08/31/21 - 10:54 am
Merck
Keytruda
Biogen
Aduhelm
Pfizer
Vir Biotechnology
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
Mon, 08/23/21 - 11:10 am
FDA
Cara Therapeutics
Vifor Pharma
Korsuva
Kadmon
belumosudil
Bristol Myers Squibb
Opdivo
Merck
Eisai
Keytruda
GSK's Jemperli follows Merck's Keytruda with FDA nod to target certain tumors regardless of location
Fierce Pharma
Wed, 08/18/21 - 11:08 am
GSK
Jemperli
FDA
cancer
Merck
Keytruda
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Thu, 08/12/21 - 12:35 pm
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
FDA starts speedy review of Keytruda for adjuvant kidney cancer
Pharmaforum
Wed, 08/11/21 - 10:57 am
Merck
FDA
Keytruda
kidney cancer
Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers
Endpoints
Thu, 08/5/21 - 11:05 am
Keytruda
Merck
clinical trials
melanoma
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
EP Vantage
Fri, 07/30/21 - 11:04 am
FDA
Axsome Therapeutics
Sanofi
Merck
Pompe disease
depression
kidney cancer
Keytruda
Merck rebounds to win a milestone immunotherapy approval in early breast cancer
BioPharma Dive
Tue, 07/27/21 - 04:39 pm
FDA
Merck
Keytruda
breast cancer
Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer
Endpoints
Thu, 07/22/21 - 10:14 pm
Merck
Keytruda
Lenvima
endometrial cancer
FDA
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
Mon, 07/12/21 - 11:08 am
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
FDA Expands Approval for Keytruda in Locally Advanced Cutaneous SCC
BioSpace
Tue, 07/6/21 - 11:18 pm
Merck
Keytruda
cutaneous squamous cell carcinoma
FDA
Merck to withdraw dangling accelerated approval for Keytruda in third-line stomach cancer
Endpoints
Thu, 07/1/21 - 11:09 pm
Merck
Keytruda
oncology
stomach cancer
FDA
Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study
BioSpace
Wed, 06/30/21 - 09:58 pm
Merck
Alpine Immune Sciences
cancer
ALPN-202
Keytruda
Merck's Keytruda extends life for cervical cancer patients in first-in-class win
Fierce Pharma
Tue, 06/22/21 - 12:29 pm
Merck
Keytruda
cervical cancer
clinical trials
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer
Fierce Pharma
Thu, 06/3/21 - 11:05 pm
ASCO 2021
Merck
Keytruda
kidney cancer
Sutent
Pfizer
Xilio inks Merck deal to run checkpoint inhibitor combo trial
Fierce Biotech
Tue, 05/25/21 - 11:15 am
Xilio Therapeutics
Merck
Keytruda
XTX101
clinical trials
solid tumors
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »